华东医药:2025年第三季度报告(英文版)

Security code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2025-098
Huadong Medicine Co., Ltd.
Third Quarterly Report 2025
The Company and all members of the Board of Directors hereby guarantee that the
information presented in this report is authentic, accurate and complete and free of any false
records, misleading statements or material omissions.
Important Declaration:
1. The Board of Directors, directors and senior managers of Huadong Medicine Co., Ltd. (hereinafter referred to
as the "Company") hereby guarantee that the information presented in the Report is authentic, accurate and
complete and free of false records, misleading statements or material omissions, and shall undertake individual
and joint legal liabilities.
2. The Company's legal representative, the officer in charge of accounting, and the head of accounting
department (accounting supervisor) hereby declare that the financial information in this quarterly report is
authentic, accurate and complete.
3. Has the Third Quarterly Financial Accounting Report been audited
□Yes No
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese
and other language version of public notice, they should ensure the content of both versions are the same. In the
case of discrepancy, the original version in Chinese shall prevail.
I. Key Financial Data
(I) Key accounting data and financial indicators
Does the Company need to retroactively adjust or restate the accounting data of previous years
□Yes No
Increase or decrease Change from the
during the current Beginning of the year to beginning of the year to
Current reporting reporting period the end of the reporting the end of the reporting
period compared with the period period over the end of
same period of last last year
year
Operating revenue 10,989,214,170.47 4.53% 32,664,143,135.68 3.77%
(RMB)
Net profit attributable
to shareholders of the 933,089,158.25 7.71% 2,747,916,019.11 7.24%
listed company (RMB)
Net profit attributable
to shareholders of the
listed company after 931,780,891.87 8.77% 2,693,515,147.85 8.53%
deduction of non-
recurring gains and
losses (RMB)
Net cash flow from
operating activities — — 2,610,851,944.18 4.17%
(RMB)
Basic earnings per 0.5389 8.45% 1.5682 7.09%
share (RMB/share)
Diluted earnings per 0.5320 7.41% 1.5666 7.02%
share (RMB/share)
Weighted average 3.79% -0.11% 11.39% -0.31%
return on equity
End of the current End of the last year Increase or decrease at the end of the current reporting
reporting period period compared with the end of the last year
Total assets (RMB) 39,928,783,200.48 37,879,046,367.15 5.41%
Owners' equity
attributable to 24,132,887,034.31 23,060,051,397.36 4.65%
shareholders of listed
companies (RMB)
……